UI Cancer Center, Quigley recruiting patients for AML study

University of Illinois Cancer Center researchers are leading a multicenter study to learn whether the combination of cancer drugs Gemtuzumab and Venetoclax can kill leukemia stem cells, thus eradicating leukemia in patients suffering from relapsed/refractory acute myeloid leukemia (AML). “As Gemtuzumab kills leukemia cells through inducing a form of cell death called apoptosis, and Venetoclax primes cancer cells to undergo apoptosis, the synergy of the combination should prove effective in patients with leukemia,”…

Continue Reading

Big Ten study tests pembrolizumab and goserelin in advanced AR+ salivary gland cancer

A Big Ten Cancer Research Consortium phase II study for adults with advanced androgen receptor-positive (AR+) salivary gland cancer will test combining the PD-1 inhibitor pembrolizumab and the androgen deprivation therapy goserelin. This study is open for accrual at the University of Illinois Cancer Center, along with other Big Ten institutions. Researchers hope to learn whether this combination is better, the same, or worse than the usual approach to treating this type of…

Continue Reading

Phase 1 human trials suggest UIC-developed breast cancer drug is safe, effective

A new type of breast cancer drug developed by University of Illinois Cancer Center members Debra Tonetti and Gregory Thatcher can help halt progression of disease and is not toxic, according to phase 1 clinical trials. The drug is specifically designed for women whose cancer has stopped responding to hormone therapy. The results are published in the journal Breast Cancer Research and Treatment. Breast cancer affects one in eight women in the United…

Continue Reading

Newly activated UI Cancer Center Clinical Trials

The following studies have recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about a study, please email cancertrials@uic.edu or call 312-355-5112. A Phase 2a Open-label Study to Investigate Safety and Tolerability (Including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination With…

Continue Reading

Newly activated UI Cancer Center Clinical Trials

The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on clinicaltrials.gov.NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History StudySponsor: National Cancer InstitutePrincipal Investigator: Oana Danciu, MDFor more information or questions about a study, please email cancertrials@uic.edu or call 312-355-5112. Learn more here

Continue Reading

EA9171: Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about a study, please email cancertrials@uic.edu or call 312-355-5112. EA9171: Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal…

Continue Reading

BRE-03: Window of Opportunity Trial of Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link below to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about a study, please email cancertrials@uic.edu or call 312-355-5112. BRE-03: Window of Opportunity Trial of Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) Sponsor: University of Illinois at Chicago…

Continue Reading

Emerald 1: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma

The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about a study, please email cancertrials@uic.edu or call 312-355-5112. Emerald 1: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus…

Continue Reading

NRG-GU008: Randomized Phase III Trial Incorporating Abiraterone Acetate With Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy

The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about a study, please email cancertrials@uic.edu or call 312-355-5112.NRG-GU008: Randomized Phase III Trial Incorporating Abiraterone Acetate With Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer…

Continue Reading

S1827: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about a study, please email cancertrials@uic.edu or call 312-355-5112. https://clinicaltrials.gov/ct2/show/NCT04155034?term=s1827&draw=2&rank=1 Sponsor: Southwest Oncology Group Collaborator: National Cancer Institute Principal Investigator: Lawrence Feldman, MD

Continue Reading